Displaying drugs 15826 - 15850 of 15905 in total
Carbuterol
Experimental
Matched Iupac: … {5-[2-(tert-butylamino)-1-hydroxyethyl]-2-hydroxyphenyl}urea …
Matched Categories: … Selective Beta 2-adrenergic Agonists …
Matched Categories: … Selective Beta 2-adrenergic Agonists …
Quifenadine
Experimental
Aluminium clofibrate
Experimental
Matched Iupac: … aluminium(3+) ion bis(2-(4-chlorophenoxy)-2-methylpropanoate) hydroxide …
Penfluridol
Experimental
Xipamide
Experimental
Matched Iupac: … 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide …
Esaxerenone
Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational
Matched Iupac: … 1-(2-hydroxyethyl)-N-(4-methanesulfonylphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide …
Indole Naphthyridinone
Experimental
Matched Iupac: … -N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2- …
6-Methylamino-5-Nitroisocytosine
Experimental
Matched Iupac: … 2-amino-6-(methylamino)-5-nitro-3,4-dihydropyrimidin-4-one …
AMG-131
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Ragaglitazar
Investigational
Matched Iupac: … (2R)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid …
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Iupac: … 5-({4-[(6-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione …
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
Tucaresol
Tucaresol has been used in trials studying the treatment of HIV Infections.
Investigational
Matched Iupac: … 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid …
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Iupac: … 1,2,4-thiadiazol-5-yl)-5-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]-octahydrocyclopenta[c]pyrrole-2- …
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
NLX-P101
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and …
Nifurpirinol
Experimental
Vet approved
Matched Iupac: … {6-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]pyridin-2-yl}methanol …
Ondelopran
Ondelopran has been used in trials studying the treatment of Alcohol Dependence.
Investigational
Matched Iupac: … 6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-3-carboxamide …
CG0070
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
Matched Description: … can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and …
Acylated ceftazidime
Experimental
Matched Iupac: … (2R)-2-[(1R)-1-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-oxoethyl …
Febantel
Experimental
Vet approved
Matched Iupac: … methyl N-{[(methoxycarbonyl)amino]({[2-(2-methoxyacetamido)-4-(phenylsulfanyl)phenyl]imino})methyl}carbamate …
LI-301
LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism...
Investigational
Matched Description: … of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and …
Lifirafenib
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Investigational
Matched Iupac: … 7,9-trien-9-yl]oxy}-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one ... 5-{[(2R,3R,4S)-3-[6-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]-5-oxatricyclo[4.4.0.0^{2,4}]deca-1(6), …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Siagoside
Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to...
Investigational
Matched Iupac: … oxane-2,2'-pyrano[3,4-b][1,4]dioxin]-3'-oneoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-hydroxyoctadec ... -4-en-2-yl]octadecanamide ... 3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2- ... yl]oxy}oxan-2-yl]oxy}-4-hydroxy-7'-(hydroxymethyl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-hexahydrospiro[ …
Matched Description: … substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and ... Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. ... Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. …
Matched Description: … substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and ... Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. ... Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. …
1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
Experimental
Displaying drugs 15826 - 15850 of 15905 in total